In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 3, 2008, Pages 547-554

  Villar, Raquel ^a   Vicente, Esther ^a   Solano, Beatriz ^a   Pérez Silanes, Silvia ^a   Aldana, Ignacio ^a   Maddry, Joseph A ^b   Lenaerts, Anne J ^c   Franzblau, Scott G ^d   Cho, Sang Hyun ^d   Monge, Antonio ^a   Goldman, Robert C ^e  

^a UNIVERSITY OF NAVARRA   (Spain)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antitubercular drugs; In vivo efficacy; Resistance

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMINOSALICYLIC ACID; CIPROFLOXACIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; PYRAZINAMIDE; QUINOXALINE 1,4 DI N OXIDE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CELL DEATH; CONTROLLED STUDY; CROSS RESISTANCE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG TUBERCULOSIS; MAXIMUM TOLERATED DOSE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; ANTITUBERCULAR AGENTS; BIOTRANSFORMATION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; MICE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; QUINOXALINES; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 49649096677     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn214     Document Type: Article

References (33)

1. Fact Sheet No. 104. www.who.int/mediacentre/factsheets/fs104 (10 May 2008, date last accessed). World Health Organization.
2. Espinal MA. The global situation of MDR-TB. Tuberculosis 2003; 83: 44-51.
3. Benatar SR. Extensively drug resistant tuberculosis - problem will get worse in South Africa unless poverty is alleviated. Br Med J 2006; 333: 705.
4. Dahle UR. Extensively drug resistant tuberculosis - beware patients lost to follow-up. Br Med J 2006; 333: 705.
5. Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-80.
6. Goldman RC, Plumley KV, Laughon BE. The evolution of extensively drug resistant tuberculosis (XDR-TB): History, status and issues for global control. Infect Disord Drug Targets 2007; 7: 73-91.
7. Lawn SD, Wilkinson R. Extensively drug resistant tuberculosis - a serious wake-up call for global health. Br Med J 2006; 333: 559-60.
8. Manissero D, Fernandez de la Hoz K. Extensive drug-resistant TB: A threat for Europe? Eurusurveillance 2006; 11: E060928.
9. Shah NS, Pratt R, Althomsons S et al. Extensively drug-resistant tuberculosis - United States, 1993-2006 (Reprinted from MMWR 2007; 56: 250-3). J Am Med Assoc 2007; 297: 1871-3.
10. Jaso A, Zarranz B, Aldana I et al. Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti- Mycobacterium tuberculosis agents. J Med Chem 2005; 48: 2019-25.
11. Montoya ME, Sainz Y, Ortega MA et al. Synthesis and anti-tuberculosis activity of some new 2-quinoxalinecarbonitriles. Farmaco 1998; 53: 570-3.
12. Ortega MA, Montoya ME, Jaso A et al. Antimycobacterial activity of new quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di- N-oxide derivatives. Pharmazie 2001; 56: 205-7.
13. Ortega MA, Sainz Y, Montoya ME et al. Synthesis and anti-tuberculosis activity of now 2-quinoxalinecarbonitrile 1,4-di-N oxides. Pharmazie 1999; 54: 24-5.
14. Ortega MA, Sainz Y, Montoya ME et al. Anti-Mycobacterium, tuberculosis agents derived from quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide. Arzneimittel-Forschung 2002; 52: 113-9.
15. Sainz Y, Montoya ME, Martinez-Crespo FJ et al. New quinoxaline 1,4-di-N-oxides for treatment of tuberculosis. Arzneimittel-Forschung 1999; 49: 55-9.
16. Jaso A, Zarranz B, Aldana I et al. Synthesis of new 2-acetyl and 2-benzoyl quinoxaline 1,4-di-N-oxide derivatives as anti- Mycobacterium tuberculosis agents. Eur J Med Chem 2003; 38 791-800.
17. Zarranz B, Jaso A, Aldana I et al. Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives. Bioorg Med Chem 2003; 11: 2149-56.
18. Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 1997; 41: 1004-9.
19. Franzblau SG, Witzig RS, McLaughlin JC et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol 1998; 36: 362-6.
20. Garnier T, Eiglmeier K, Camus JC et al. The complete genome sequence of Mycobacterium bovis. Proc Natl Acad Sci USA 2003; 100: 7877-82.
21. Cheng AFB, Yew WW, Chan EWC et al. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004; 48: 596-601.
22. Gruppo V, Johnson CM, Marietta KS et al. Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006; 50 1245-50.
23. Cooper AM, Dalton DK, Stewart TA et al. Disseminated tuberculosis in interferon-gamma gene-disrupted mice. J Exp Med 1993; 178 2243-7.
24. Lenaerts AJM, Gruppo V, Brooks JV et al. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother 2003; 47: 783-5.
25. Cho SH, Warit S, Wan BJ et al. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob, Agents Chemother 2007; 51 1380-5.
26. Goldman RC, Plumley KV, Laughon BE. The evolution of extensively drug resistant tuberculosis (XDR-TB): History, status and issues for global control. Infect Disord Drug Targets 2007; 7: 73-91.
27. Suter W, Rosselet A, Knusel F. Mode of action of quindoxin and substituted quinoxaline-di-N-oxides on Escherichia coli. Antimicrob Agents Chemother 1978; 13: 770-83.
28. Laurenzi M, Ginsberg A, Spigelman M. Challenges associated with current and future TB treatment. Infect Disord Drug Targets 2007; 7: 105-19.
29. Choi KP, Bair TB, Bae YM et al. Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F-420 biosynthesis by Mycobacterium bovis BCG. J. Bacteriol 2001; 183: 7058-66.
30. Choi KP, Kendrick N, Daniels L. Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F-420 and FO biosynthesis. J Bacteriol 2002; 184: 2420-8.
31. Manjunatha UH, Boshoff H, Dowd CS et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006; 103 431-6.
32. White LE, Suling WJ, Ross LJ et al. 2-Alkoxycarbonylamino-pyridines: Inhibitors of Mycobacterium tuberculosis FtsZ. J Antimicrob Chemother 2002; 50: 111-4.
33. Lenaerts AJ, Johnson CM, Marrieta KS et al. Significant increases in the levels of liver enzymes in mice treated with anti-tuberculosis drugs. Int J Antimicrob Agents 2005; 26: 152-8.